Peginterferon
Hepatic Insufficiency
Boehringer IngelheimPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hepatic Insufficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Azienda Ospedaliera di Padova | Phase 2 | B |
OTENABANT Pfizer | Phase 1 | CC |
Trabectedin Janssen Research & Development, LLC | Phase 1 | CC |
Alisporivir Debiopharm International SA | Phase 1 | CC |
DEXAMETHASONE Janssen Research & Development, LLC | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Peginterferon is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →